American small and medium-size companies that rely on China are scrambling to adjust their business plans in response to the escalating trade war.Traderead more
Here are the products that stand to be the most affected by China's new tariffs on $75 billion worth of U.S. goods.Marketsread more
The European Union will respond in kind if the U.S. imposes tariffs on France over digital tax plan, EU chief Donald Tusk told G-7.Technologyread more
The world's second biggest economy is past a point where it cannot ignore its enormous debt anymore, according to an analyst.China Economyread more
Trump said he will raise tariffs on $250 billion in Chinese goods to 30% and hike duties on another $300 billion in products to 15%.Politicsread more
As demand for lab monkeys continues to rise, U.S. scientists are reporting delays in research projects because they can't obtain enough animals, according to the National...Politicsread more
China said on Saturday it strongly opposes Washington's decision to levy additional tariffs on $550 billion worth of Chinese goods and warned the United States of consequences...Politicsread more
Stocks dropped after Donald Trump ordered that U.S. manufacturers find alternatives to their operations in China.US Marketsread more
The final week of August could be highly volatile as markets fret over the economy and the latest developments in trade wars.Market Insiderread more
Federal Reserve Vice Chair Richard Clarida said Friday that the global economy has deteriorated in the past month.Marketsread more
The latest escalation in the trade war ups the odds the economy will fall into recession and that the Fed will aggressively cut rates.Market Insiderread more
Cannabis stocks are the "next huge growth area" and the plant has "staggering" possibilities for medical use, according to one advisor to wealthy families.
"If you want to be in something that's very growthy, and actually legitimate as it is legalized and controlled properly, I think this is the place to go," Carol Pepper of Pepper International told CNBC's "Squawk Box Europe" on Friday.
The New York Stock Exchange and Nasdaq both listed cannabis companies in 2018 when Canopy Growth and the Cronos Group went public on the indexes. Both firms are based in Canada, where recreational marijuana is now legal. Canopy Growth stock has risen more than 65 percent year-to-date, while over the same period Cronos has risen more than 115 percent.
Pepper said legalization in Canada had "blown through expectations" and the success had reached the point where firms based there were now exporting to Europe.
"The medical applications for cannabis are staggering. The research is being done and I really think this is next huge growth area," she said, noting evidence of the drug's efficacy in treatment of arthritis and epilepsy.
The wealth manager also rejected a suggestion that cannabis stocks would mirror the bitcoin frenzy, which saw asset prices spike to the highs of over $19,000 and crash to trade at around $3,940 currently , stating that cannabis is a physical product with defined benefits.
"I think it is a phenomenal plant that is going to a lot of good for the planet and I'm glad it is finally being legalized."
Ten U.S. states and the District of Columbia have legalized the crop, even though federal law bans it.
Pepper predicted that big U.S. tobacco and drinks companies will take control of the industry once more legal prohibition is removed around the world.
Many burgeoning cannabis companies control the supply chain from growth of the plaint through to the final sale of derived oils, cream and edibles.
Pepper said this was likely to remain an industry trend as guaranteeing a stable level of chemical within each plant was scientifically tricky.
"If you are going to do EUGMP standard cannabis, which means it can come into Europe, you are going to have to be able to control the level of the various chemicals in the plant," she said.